Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.59 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 4/20 | 0.51 |
| ▸ | CTSL | P07711 | 4/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12052764 | 1.00 | TRPM8 (0.59) | TRPM8CTRB1ALDH1A1ALOX15CTSB | |
| SCHEMBL1709148 | 1.00 | TRPM8 (0.59) | TRPM8CTRB1ALDH1A1ALOX15CTSB | |
| SCHEMBL1701917 | 1.00 | TRPM8 (0.59) | TRPM8CTRB1ALDH1A1ALOX15CTSB | |
| SCHEMBL17452286 | 1.00 | TRPM8 (0.59) | TRPM8CTRB1ALDH1A1ALOX15CTSB | |
| SCHEMBL1701749 | 1.00 | TRPM8 (0.59) | TRPM8CTRB1ALDH1A1ALOX15CTSB | |
| SCHEMBL8100463 | 0.87 | CTSL (0.51) | TRPM8CTRB1ALDH1A1ALOX15CTSB | |
| SCHEMBL18257510 | 0.87 | CTSK (0.56) | TRPM8CTSBCTSLCTSSCTSK | |
| SCHEMBL8276388 | 0.87 | CTSK (0.56) | TRPM8CTSBCTSLCTSSCTSK | |
| SCHEMBL1701841 | 0.87 | CTSL (0.51) | TRPM8CTRB1ALDH1A1ALOX15CTSB | |
| SCHEMBL8100330 | 0.87 | CTSL (0.51) | TRPM8CTRB1ALDH1A1ALOX15CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088762-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8080576-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080545-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144648-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7691852-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20070293465-A1 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088762-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | TRPM8 3475/4885CTRB1 455/4885ALDH1A1 1307/4885 |
| US-20070293465-A1 | Compounds for enzyme inhibition | PSME1, PSMB1, PSME3 | TRPM8 3475/4885CTRB1 455/4885ALDH1A1 1307/4885 |
| US-20100144648-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | TRPM8 3475/4885CTRB1 455/4885ALDH1A1 1307/4885 |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | TRPM8 3475/4885CTRB1 455/4885ALDH1A1 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.